Cargando…
Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is a widespread genetic disease that leads to renal failure in the majority of patients. The very first pharmacological treatment, tolvaptan, received Food and Drug Administration approval in 2018 after previous approval in Europe and other countr...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295603/ https://www.ncbi.nlm.nih.gov/pubmed/30581563 http://dx.doi.org/10.1093/ckj/sfy089 |